Pyruvate Kinase Deficiency Related Hemolytic Anemia Therapeutics
1. Pyrukynd patent expiration
Treatment: Method for administering mitapivat or a salt of mitapivat to mitigate drug interactions in patients with hemolytic anemia that are taking moderate cyp3a inducers; Method for increasing the lifetime of...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(5 years from now) | |
| USRE49582 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(5 years from now) | |
| US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11878049 | AGIOS PHARMS INC | Mitapivat therapy and modulators of cytochrome P450 |
Jul, 2041
(15 years from now) | |
| US11793806 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Apr, 2033
(7 years from now) | |
| US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(6 years from now) | |
| US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(6 years from now) | |
| US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Dosage: TABLET
More Information on Dosage
PYRUKYND family patents
